EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Assessment of Cell-Free DNA (cfDNA) as a Biomarker in Colorectal Malignancies: A Longitudinal Observational Cohort Study

Anura Kantak, Sunil Kumar, Atul Sharma, Sandeep Bhoriwal, Naveen Kumar, R. Chethan, Mayank Singh, Ashna Gupta, Sanchita Mitra, Raja Pramanik

Indian Journal of Medical and Paediatric Oncology · 01.02.2026 · 47 (01) · A01-A58

DOI: 10.1055/s-0046-1818501 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.02.2026. Verfasst von Anura Kantak und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims and Objectives: Globally, cfDNA and circulating tumor DNA (ct-DNA) have gained recognition in colorectal malignancies, for prognostic evaluation, MRD assessment, and guiding therapy decisions. However, data on cfDNA from India remain limited. We aimed to quantify baseline cfDNA and understand the association of their clinicopathological features and survival with cfDNA and its dynamics. Materials and Methods: We recruited 51 patients with newly diagnosed CRC. Cohort A had patients with curative intent ( n = 29), while Cohort B included patients with palliative intent ( n = 22). 5 mL blood was collected in EDTA tubes at two-time points: baseline (Sample 1) and post-therapy (Sample 2). Sample 2 was collected either at the end of neoadjuvant therapy or 24 hours post-surgery in cohort A. In cohort B, sample 2 was collected after 3 months of first-line therapy. cfDNA was isolated using the Maxwell-RSC-ccfDNA isolation kit and quantified using SYBR-Green real-time-PCR of the beta-globin gene. No intervention was planned on cfDNA levels Results: Baseline characteristics of all 51 patients are shown in [ Table 1 ]. Mean baseline cfDNA levels were 1.63 × 2.91 ng/µL. No significant association was observed between TNM stage, node positivity, histology, CEA, and baseline cfDNA levels. Baseline cfDNA levels did not show a significant association with clinical response ([ Table 2A ], [ B ]), progression-free survival (PFS), or overall survival (OS). Longitudinal samples (1 and 2) were available for 15 patients. We found fair concordance between cfDNA dynamics (rise or fall) and clinical response except for 4 discordant responses ([ Table 3 ]). The possible reason for discordant responses could be attributed to analytical failures. cfDNA responders had a trend toward improved PFS and OS ( p = NS). Fig. 1 Study schema. Table 1 Baseline characteristics Characteristics n (%) Total patients ( n ) 51 Age (years), median (IQR) 44 (18–71) Gender Males 31 (60.8%) Females 20 (39.2%) TNM stage I and II 7 (13.7%) III 19 (37.2%) IVA 9 (17.6%) IVB and IVC 16 (31.3%) Tumor (T) stage T1/T2 7 (13.7%) T3 20 (39.2%) T4 24 (47.1%) Node (N) stage N0 9 (17.6%) N1 18 (35.3%) N2 21 (41.2%) N3 3 (5.9%) Metastasis (M) stage M0 26 (51%) M1 25 (49%) Histology Well-differentiated 4 (7.8%) Moderately differentiated 23 (45.1%) Poorly differentiated 24 (47.1%) dMMR 3 (5.8%) RAS/RAF mutation 2 (3.9%) Her2 expression 1 (2%) CEA (ng/mL), median (IQR) 34 (3.8–94) Table 2A Clinical response versus baseline cfDNA: cohort A a (Response evaluated in 23 patients) Baseline cfDNA < 1.63 ng/µL ( n = 19) Baseline cfDNA ≥ 1.63 ng/µL ( n = 4) CR/PR/SD ( n = 17) 13 4 p = 0.26 (Fisher’s exact) PD ( n = 6) 6 0 a 4 patients of ca colon who underwent upfront surgery are not included in this analysis. Table 2B Clinical response versus baseline cfDNA: cohort B (Response evaluated in 20 patients) Baseline cfDNA < 1.63 ng/µL ( n = 15) Baseline cfDNA ≥ 1.63 ng/ µL ( n = 5) PR/SD ( n = 9) 8 1 p = 0.22 (Fisher’s exact) PD ( n = 11) 7 4 Table 3 Clinical response versus cfDNA dynamics[ a ] Fall in cfDNA( n = 7) Rise in cfDNA( n = 7) PR/SD ( n = 9) 6 3 p = 0.26 (Fisher’s exact) PD ( n = 5) 1 4 a 1 longitudinal sample post-surgery is excluded from this analysis. Conclusion: There was no significant association between baseline cfDNA and clinicopathological profile. cfDNA dynamics were concordant with clinical response in colorectal malignancies, with the exception of four discordant responses. Publication History Article published online: 20 February 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

Zitieren

APA

Kantak, A., Kumar, S., Sharma, A., Bhoriwal, S., Kumar, N., Chethan, R., Singh, M., Gupta, A., Mitra, S., & Pramanik, R. (2026). Assessment of Cell-Free DNA (cfDNA) as a Biomarker in Colorectal Malignancies: A Longitudinal Observational Cohort Study. Indian Journal of Medical and Paediatric Oncology, 47(01), A01-A58. https://doi.org/10.1055/s-0046-1818501

Vancouver

Kantak A, Kumar S, Sharma A, Bhoriwal S, Kumar N, Chethan R, et al. Assessment of Cell-Free DNA (cfDNA) as a Biomarker in Colorectal Malignancies: A Longitudinal Observational Cohort Study. Indian Journal of Medical and Paediatric Oncology. 2026;47(01):A01-A58. doi:10.1055/s-0046-1818501

BibTeX
@article{Kantak2026,
  author = {Kantak, Anura and Kumar, Sunil and Sharma, Atul and Bhoriwal, Sandeep and Kumar, Naveen and Chethan, R. and Singh, Mayank and Gupta, Ashna and Mitra, Sanchita and Pramanik, Raja},
  title = {Assessment of Cell-Free DNA (cfDNA) as a Biomarker in Colorectal Malignancies: A Longitudinal Observational Cohort Study},
  journal = {Indian Journal of Medical and Paediatric Oncology},
  year = {2026},
  volume = {47},
  number = {01},
  pages = {A01--A58},
  doi = {10.1055/s-0046-1818501}
}
Kostenlos starten →